单克隆SARS-CoV-2抗体作为暴露前预防的健康结局与成本效果
本研究为经济评价,基于决策分析模型,参数取自636例COVID-19高风险个体(平均年龄63岁,54%男性;21% BMI≥30,9.4%血液系统恶性肿瘤,17%移植后,23.9%病前使用免疫抑制剂)。在感染概率18%、有效率25%时,模型计算短期病房入住减少42%、ICU入住减少31%、死亡减少34%;药价275美元且有效率≥75%时可节约成本;有效率100%时病房入住减少70%、ICU入住减少97%、死亡减少92%。药价需分别降至550美元(每QALY成本<22000美元)和2200美元(每QALY成本22000–88000美元)才具成本效果。
要点
- 感染概率18%、有效率25%时,mAbs PrEP模型计算短期病房入住减少42%、ICU入住减少31%、死亡减少34%。
- 药价275美元且有效率≥75%时可实现节约成本;有效率100%时病房入住减少70%、ICU入住减少97%、死亡减少92%。
- 药价需降至550美元才使每QALY成本低于22000美元,降至2200美元才使每QALY成本在22000–88000美元之间。
- 队列中21% BMI≥30、9.4%血液系统恶性肿瘤、17%移植后、23.9%病前使用免疫抑制剂,均为重症高风险人群。
适用人群与场景
- 636例COVID-19个体,平均(SD)年龄63(18)岁,341例(54%)男性;137例(21%)BMI≥30,60例(9.4%)血液系统恶性肿瘤,108例(17%)移植后,152例(23.9%)COVID-19前使用免疫抑制剂。
研究设计与关键结果
- 经济评价采用决策分析模型,参数取自高风险COVID-19个体的医疗结局与利用数据,SARS-CoV-2感染概率、mAbs PrEP有效性和药价均设可变;成本从第三方支付方角度收集;数据分析时间为2021年9月至2022年12月。
- 在感染概率18%、有效率25%时,模型计算短期病房入住减少42%、ICU入住减少31%、死亡减少34%。
- 药价275美元且有效率≥75%时可获得节约成本情景;有效率100%时mAbs PrEP可减少病房入住70%、ICU入住97%、死亡92%。
- 药价需降至550美元才使每QALY获得成本低于22000美元,降至2200美元才使成本效果比在22000–88000美元/QALY之间。
证据类型、等级与局限
- 证据类型:经济评价(决策分析模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在疫情波初期(高感染概率)且有效率≥75%、药价275美元时,使用mAbs PrEP预防SARS-CoV-2感染可节约成本。
- 作者认为,当更新的mAbs PrEP组合可用时,应制定实施指导以确保快速推广;倡导使用mAbs PrEP并批判性讨论药价对确保不同疫情场景下的成本效果是必要的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Pre-exposure prophylaxis with neutralizing SARS-CoV-2 monoclonal antibodies (mAbs PrEP) prevents infection and reduces hospitalizations and the duration thereof for COVID-19 and death among high-risk individuals. However, reduced effectiveness due to a changing SARS-CoV-2 viral landscape and high drug prices remain substantial implementation barriers.
OBJECTIVE: To assess the cost-effectiveness of mAbs PrEP as COVID-19 PrEP.
DESIGN, SETTING, AND PARTICIPANTS: For this economic evaluation, a decision analytic model was developed and parameterized with health care outcome and utilization data from individuals with high risk for COVID-19. The SARS-CoV-2 infection probability, mAbs PrEP effectiveness, and drug pricing were varied. All costs were collected from a third-party payer perspective. Data were analyzed from September 2021 to December 2022.
MAIN OUTCOMES AND MEASURES: Health care outcomes including new SARS-CoV-2 infections, hospitalization, and deaths. The cost per death averted and cost-effectiveness ratios using a threshold for prevention interventions of $22 000 or less per quality-adjusted life year (QALY) gained.
RESULTS: The clinical cohort consisted of 636 individuals with COVID-19 (mean [SD] age 63 [18] years; 341 [54%] male). Most individuals were at high risk for severe COVID-19, including 137 (21%) with a body mass index of 30 or higher, 60 (9.4%) with hematological malignant neoplasm, 108 (17%) post-transplantation, and 152 (23.9%) who used immunosuppressive medication before COVID-19. Within the context of a high (18%) SARS-CoV-2 infection probability and low (25%) effectiveness the model calculated a short-term reduction of 42% ward admissions, 31% intensive care unit (ICU) admissions, and 34% deaths. Cost-saving scenarios were obtained with drug prices of $275 and 75% or higher effectiveness. With a 100% effectiveness mAbs PrEP can reduce ward admissions by 70%, ICU admissions by 97%, and deaths by 92%. Drug prices, however, need to reduce to $550 for cost-effectiveness ratios less than $22 000 per QALY gained per death averted and to $2200 for ratios between $22 000 and $88 000.
CONCLUSIONS AND RELEVANCE: In this study, use of mAbs PrEP for preventing SARS-CoV-2 infections was cost-saving at the beginning of an epidemic wave (high infection probability) with 75% or higher effectiveness and drug price of $275. These results are timely and relevant for decision-makers involved in mAbs PrEP implementation. When newer mAbs PrEP combinations become available, guidance on implementation should be formulated ensuring a fast rollout. Nevertheless, advocacy for mAbs PrEP use and critical discussion on drug prices are necessary to ensuring cost-effectiveness for different epidemic settings.
参考来源
- Popping S, Nichols BE, Appelman B, et al. Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis. JAMA Netw Open. 2023. PMID: 37410460. doi:10.1001/jamanetworkopen.2023.21985
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。